Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$483.00 USD

483.00
2,259,829

-15.73 (-3.15%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Vertex Pharmaceuticals (VRTX) Recently Broke Out Above the 20-Day Moving Average

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Vertex Pharmaceuticals (VRTX) Just Reclaimed the 200-Day Moving Average

by Zacks Equity Research

Should investors be excited or worried when a stock crosses above the 200-day simple moving average?

CRISPR's (CRSP) CAR-T Cell Therapy Gets FDA's RMAT Designation

by Zacks Equity Research

The FDA grants a Regenerative Medicine Advanced Therapy designation to CRISPR Therapeutics' (CRSP) CTX110 targeting CD19+ B-cell malignancies.

CRISPR (CRSP) to Begin Clinical Study on Diabetes Therapy Drug

by Zacks Equity Research

CRISPR Therapeutics (CRSP) receives clearance from Health Canada to initiate clinical studies for VCTX210, its investigational therapy for the treatment of type 1 diabetes.

Wall Street Analysts Think Vertex (VRTX) Could Surge 36%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Vertex (VRTX) points to a 36.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Allogene (ALLO) Misses on Q3 Earnings, Addresses Clinical Hold

by Zacks Equity Research

Allogene (ALLO) misses earnings estimates for the third quarter. However, the stock rises in after-market trading.

Emergent (EBS) Q3 Earnings Miss, Contract Revenue View Down

by Zacks Equity Research

Emergent's (EBS) third-quarter 2021 earnings and sales miss estimates. The company tightens the revenue guidance on lower anticipated revenues from the CDMO segment. Stock down in after-market trading.

Moderna (MRNA) Q3 Earnings Miss, COVID-19 Vaccine Brings $5B

by Zacks Equity Research

Moderna's (MRNA) COVID-19 vaccine sales miss expectations. The company delivers 208 million doses of its COVID-19 vaccine during the third quarter. Stock declines in pre-market.

Sarepta (SRPT) Q3 Earnings Beat, 2021 Sales View Raised

by Zacks Equity Research

Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the third quarter. The company also raises revenues guidance for the year. Stock up in after-market trading.

Company News for Nov 4, 2021

by Zacks Equity Research

Companies In The News Are: VRTX, ATH, DISCA, MAR.

CRISPR Therapeutics (CRSP) Q3 Earnings Beat, Revenues Lag

by Zacks Equity Research

CRISPR Therapeutics (CRSP) reports narrower-than-expected Q3 loss. Yet, revenues miss estimates for the third quarter of 2021.

Amarin (AMRN) Q3 Earnings Top, Vascepa Sales Decline Y/Y

by Zacks Equity Research

Amarin's (AMRN) reports lower sales volume for its drug, Vascepa, in the United States during the third quarter. The company's stock falls in pre-market trading.

Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises '21 View

by Zacks Equity Research

Vertex Pharmaceuticals' (VRTX) earnings and sales beat estimates for the third quarter of 2021. The company raises its product revenue guidance for the year.

Halozyme (HALO) Beats on Q3 Earnings, Tweaks 2021 Guidance

by Zacks Equity Research

Halozyme (HALO) third-quarter earnings and sales beat estimates. The company raises the lower end of its previously guided range for earnings and revenues for 2021. Stock up.

Vertex Pharmaceuticals (VRTX) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Vertex (VRTX) delivered earnings and revenue surprises of 14.10% and 7.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Cassava Sciences (SAVA) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Investors will watch for updates on its lead candidate, sumifilam, for Alzheimer's disease in Cassava's (SAVA) Q3 earnings call.

Will Eylea, Dupixent, REGEN COV Aid Regeneron (REGN) Q3 Earnings?

by Zacks Equity Research

Regeneron's third-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.

CVS Health (CVS) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

CVS Health's (CVS) consumer-centric digital approach to administering vaccines across the nation is expected to have strongly contributed to its Q3 performance.

Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Volume growth of Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Strong surgeon registrations of the Signature One surgical planning system for shoulder procedures are likely to have driven Zimmer Biomet's (ZBH) growth in Q3.

4 Big Drug, Biotech Stocks Set to Beat Q3 Earnings Estimates

by Zacks Equity Research

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

Repligen (RGEN) Q3 Earnings and Sales Beat, 2021 View Up

by Zacks Equity Research

Repligen's (RGEN) third-quarter earnings and revenues beat estimates. The company raises its guidance for 2021. Resultantly, the stock rises.

Why Earnings Season Could Be Great for Vertex Pharmaceuticals (VRTX)

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

VRTX vs. PRTA: Which Stock Is the Better Value Option?

by Zacks Equity Research

VRTX vs. PRTA: Which Stock Is the Better Value Option?

Charles River (CRL) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Robust demand for research models and the Vigene Biosciences buyout are likely to have contributed to growth for Charles River (CRL).